BIAF Discusses Veteran Lung Cancer Screening Innovations; No Material Change to Thesis

What happened

bioAffinity discussed its CyPath Lung test for veterans, highlighting a program with Philips and 4DMedical. The news reinforces a potential catalyst for VA/DoD ordering, but the company still faces severe cash burn and dilution risk. Q1 revenue fell 36% to $1.35M, CyPath Lung revenue rose to $361K, but operating cash burn was $3.23M. The June raise added only ~$2.6M net, and shares outstanding increased to 6.28M. Until Q2 results prove CyPath can drive consolidated revenue growth and reduce burn, the investment thesis remains cautious.

Implication

Investors should await Q2 2026 results for evidence that CyPath Lung revenue exceeds $500K and consolidated revenue grows, reducing the need for further dilution. The VA channel could provide institutional validation, but it remains unproven. A better entry point would be after the company demonstrates improved cash flow and revenue mix.

Thesis delta

The news itself does not alter the base-case thesis of funding risk. However, it increases the probability of the bull scenario (20% chance) if VA ordering accelerates. The core rating remains WAIT until Q2 numbers confirm CyPath is scaling fast enough to offset burn.